COMP <GO>
ELOX vs INKT // RETURN ON INVESTED CAPITAL (ROIC)
Eloxx Pharmaceuticals Inc. (NASDAQ) VS. MiNK Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ELOX 0
— INKT 4
■ METRIC PARITY
LAST: $13.45 (+1.89%) • MKT CAP: $53.3M
roic
-35.00%
LAST: $10.53 (-3.17%) • MKT CAP: $55.5M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELOX VS. INKT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELOX | INKT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.87% | -10.68% | -1.19 | INKT | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | INKT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 46.1 | -0.70 | INKT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $53.3M | $55.5M | -$2.2M | INKT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELOX REV | INKT REV | ELOX GROSS % | INKT GROSS % | ELOX FCF | INKT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$6.3M | -$5.9M |
| FY 2024 | $6.4M | $0 | — | — | -$4.7M | -$9.6M |
| FY 2023 | $0 | $0 | — | — | -$14.3M | -$15.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELOX // BETA —
INKT // BETA —